Worth Venture Partners’s SELLAS Life Sciences SLS Stock Holding History

Worth Venture Partners’s Portfolio SLS Stock Details SLS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-214,093	Closed	-$567K	–	125
2020 Q3	$567K	Buy	+214,093	New	+$587K	0.47%	54

Other funds holding SLS

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Equitable Holdings New York $16.7B AUM 24.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Virtu Financial New York $3.18B AUM 65.92% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

EGM

Engineers Gate Manager New York $7.71B AUM 24.88% 1-Year Est. Return

Worth Venture Partners's SLS Position: Q4 2020 in Review

Worth Venture Partners sold out of SELLAS Life Sciences (SLS) in Q4 2020, closing a stake of 214,093 shares — an estimated $567K sold.

Worth Venture Partners first reported a position in SLS in Q3 2020 and held it in 1 quarter. The position peaked at $567K in Q3 2020. 21 funds tracked by Wall St. Rank hold SLS as of Q4 2020.

Worth Venture Partners reported no remaining SELLAS Life Sciences position as of Q4 2020 after selling out during the quarter.
Worth Venture Partners sold 214,093 SELLAS Life Sciences shares in Q4 2020, an estimated $567K.
Worth Venture Partners first reported a position in SELLAS Life Sciences in Q3 2020 and held it in 1 quarter.
Worth Venture Partners's SELLAS Life Sciences position peaked at $567K in Q3 2020.
21 funds tracked by Wall St. Rank held SELLAS Life Sciences as of Q4 2020.

Based on Worth Venture Partners's 13F filing for Q4 2020, filed 17 Feb 2021.